Patents by Inventor Sibasish Paul

Sibasish Paul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230193266
    Abstract: Improved compositions and methods for treating a disease or disorder through target exon skipping, and preferably muscular dystrophy by administering antisense thiomorpholino molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping to produce a functional Dystrophin protein.
    Type: Application
    Filed: September 27, 2022
    Publication date: June 22, 2023
    Inventors: Marvin Caruthers, Sibasish Paul, Rakesh N. Veedu, Katarzyna Jastrzebska, Heera Krishna
  • Patent number: 11479772
    Abstract: Improved compositions and methods for treating a disease or disorder through target exon skipping, and preferably muscular dystrophy by administering antisense thiomorpholino molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping to produce a functional Dystrophin protein.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: October 25, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Marvin Caruthers, Sibasish Paul, Rakesh N. Veedu, Katarzyna Jastrzebska, Heera Krishna
  • Publication number: 20220144867
    Abstract: Amine substituted morpholino oligonucleotides, other than the classical N,N-dimethylamino PMO analogue, and methods of efficiently synthesizing these oligonucleotides with high yield are provided. Morpholino oligonucleotides having thiophosphoramidate, phosphoramidate, and alkyl phosphoramidate linkers. Chimeras containing unmodified DNA/RNA and other analogs of DNA/RNA can be prepared. These oligonucleotides form duplexes with complementary DNA or RNA that are more stable than natural DNA or DNA/RNA complexes, are active with RNAse H1, and may be transfected into cells using standard lipid reagents. These analogues are therefore useful for numerous applications.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Inventors: Marvin CARUTHERS, Sibasish PAUL
  • Patent number: 11230565
    Abstract: Amine substituted morpholino oligonucleotides, other than the classical N,N-dimethylamino PMO analogue, and methods of efficiently synthesizing these oligonucleotides with high yield are provided. Morpholino oligonucleotides having thiophosphoramidate, phosphoramidate, and alkyl phosphoramidate linkers. Chimeras containing unmodified DNA/RNA and other analogs of DNA/RNA can be prepared. These oligonucleotides form duplexes with complementary DNA or RNA that are more stable than natural DNA or DNA/RNA complexes, are active with RNAse H1, and may be transfected into cells using standard lipid reagents. These analogues are therefore useful for numerous applications.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: January 25, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Marvin Caruthers, Sibasish Paul
  • Publication number: 20200308586
    Abstract: Improved compositions and methods for treating a disease or disorder through target exon skipping, and preferably muscular dystrophy by administering antisense thiomorpholino molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping to produce a functional Dystrophin protein.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 1, 2020
    Inventors: Marvin Caruthers, Sibasish Paul, Rakesh N. Veedu, Katarzyna Jastrzebska, Heera Krishna
  • Publication number: 20190218236
    Abstract: Amine substituted morpholino oligonucleotides, other than the classical N,N-dimethylamino PMO analogue, and methods of efficiently synthesizing these oligonucleotides with high yield are provided. Morpholino oligonucleotides having thiophosphoramidate, phosphoramidate, and alkyl phosphoramidate linkers. Chimeras containing unmodified DNA/RNA and other analogs of DNA/RNA can be prepared. These oligonucleotides form duplexes with complementary DNA or RNA that are more stable than natural DNA or DNA/RNA complexes, are active with RNAse H1, and may be transfected into cells using standard lipid reagents. These analogues are therefore useful for numerous applications.
    Type: Application
    Filed: March 20, 2019
    Publication date: July 18, 2019
    Inventors: Marvin CARUTHERS, Sibasish PAUL
  • Patent number: 9914745
    Abstract: Morpholino-based oligomers suitable as antisense agent comprising modifications of phosphorodiamidate backbone or modification with 5-substituted pyrimidines of morpholino compound that is soluble in culture medium and sufficient for cell penetration thereby eliminating the need for injecting into the cells. Monomers comprising the said oligomers and its method of manufacture, method of manufacture of the said oligomers and its dye, fluorophore, drug, biomolecule conjugate wherein the said oligomers find different end use but not limited to regulation of gene expression, tissue culture with improved transfection efficiency and related studies on cellular transfection.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: March 13, 2018
    Assignee: INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE
    Inventors: Surajit Sinha, Sankha Pattanayak, Sibasish Paul, Bappaditya Nandi
  • Publication number: 20120296087
    Abstract: Morpholino-based oligomers suitable as antisense agent comprising modifications of phosphorodiamidate backbone or modification with 5-substituted pyrimidines of morpholino compound that is soluble in culture medium and sufficient for cell penetration thereby eliminating the need for injecting into the cells. Monomers comprising the said oligomers and its method of manufacture, method of manufacture of the said oligomers and its dye, flurophore, drug, biomolecule conjugate wherein the said oligomers find different end use but not limited to regulation of gene expression, tissue culture with improved transfection efficiency and related studies on cellular transfection.
    Type: Application
    Filed: August 10, 2010
    Publication date: November 22, 2012
    Applicant: INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE
    Inventors: Surajit Sinha, Sankha Pattanayak, Sibasish Paul, Bappaditya Nandi